European Metabolic Disorder Therapeutics Market
European Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026 Update Available - Forecast 2024-2030
European metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.4% during the forecast period. Rising prevalence of metabolic disorders have been reported in the region, which is accelerating the growth of the market. According to the International Diabetes Federation (IDF), an estimated 59 million adults (20-79 years) were suffering from diabetes in the Europe Region. Europe has the largest number of adolescents and children (0-19 years) have type 1 diabetes, which is 296,500. Diabetes is a form of metabolic diseases that disrupt normal metabolism. Diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others. Rosiglitazone (Avandia) is intended for use as an adjunct to exercise and diet to improve glycemic control in adults suffering from type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR?)-responsive genes that participate in the regulation of fatty acid metabolism.
Based on country, the market is classified into UK, Germany, France, Spain, Italy, and Rest of Europe. UK is estimated to hold potential share in the market coupled with the significant prevalence of metabolic disorders in the country. As per the estimation by the Health Survey for England 2017, 28.7% of adults in England were obese and a further 35.6% are overweight. This leads to an increasing demand for metabolic drugs such as Orlistat (Xenical) and Phentermine. Orlistat (Xenical) works by reducing fat absorption by nearly 30%.
Some crucial players in the market include Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, and AstraZeneca plc. Partnerships and collaborations is one of the major strategies adopted by the market players to remain competitive in the market. For instance, in March 2020, AstraZeneca plc declared partnership with Silence Therapeutics for discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics to treat CVD, renal, respiratory, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung.
Research Methodology
The market study of the European metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
- European Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
- European Metabolic Disorder Therapeutics Market Research and Analysis by Disease
The Report Covers
- Comprehensive research methodology of the European metabolic disorder therapeutics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European metabolic disorder therapeutics market.
- Insights about market determinants which are stimulating the European metabolic disorder therapeutics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. European Metabolic Disorder Therapeutics Market by Therapy
5.1.1. Drug Therapy
5.1.2. Gene Therapy
5.1.3. Cellular Transplantation
5.1.4. Enzyme Replacement Therapy
5.1.5. Others
5.2. European Metabolic Disorder Therapeutics Market by Disease
5.2.1. Obesity
5.2.2. Diabetes
5.2.3. Lysosomal Storage Disease
5.2.4. Hypercholesterolemia
5.2.5. Others
6. Regional Analysis
6.1. UK
6.2. Germany
6.3. France
6.4. Spain
6.5. Italy
6.6. Rest of European
7. Company Profiles
7.1. AbbVie Inc.
7.2. Actelion Pharmaceuticals Ltd.
7.3. AstraZeneca plc
7.4. Boehringer Ingelheim GmbH
7.5. Bristol-Myers Squibb Co.
7.6. Merck KGaA
7.7. Novo Nordisk A/S
7.8. Orchard Therapeutics plc
7.9. Sanofi S.A.
7.10. Shire Pharmaceuticals Group plc
7.11. Silence Therapeutics
1. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
2. EUROPEAN DRUG THERAPY FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
3. EUROPEAN GENE THERAPY FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
4. EUROPEAN CELLULAR TRANSPLANTATION FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
5. EUROPEAN ENZYME REPLACEMENT THERAPY FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
6. EUROPEAN OTHER METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
7. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
8. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR OBESITY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
9. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR DIABETES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
10. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
11. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR HYPERCHOLESTEROLEMIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
12. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
13. UK METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
14. UK METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
15. GERMANY METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
16. GERMANY METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
17. FRANCE METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
18. FRANCE METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
19. SPAIN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
20. SPAIN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
21. ITALY METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
22. ITALY METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
23. REST OF EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
24. REST OF EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
1. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET SHARE BY THERAPY, 2019 VS 2026 (%)
2. EUROPEAN DRUG THERAPY FOR METABOLIC DISORDER MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. EUROPEAN GENE THERAPY FOR METABOLIC DISORDER MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
4. EUROPEAN CELLULAR TRANSPLANTATION FOR METABOLIC DISORDER MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
5. EUROPEAN ENZYME REPLACEMENT THERAPY FOR METABOLIC DISORDER MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
6. EUROPEAN OTHER METABOLIC DISORDER THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
7. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET SHARE BY DISEASE, 2019 VS 2026 (%)
8. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR OBESITY MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
9. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR DIABETES MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
10. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR LYSOSOMAL STORAGE DISEASE MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
11. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR HYPERCHOLESTEROLEMIA MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
12. EUROPEAN METABOLIC DISORDER THERAPEUTICS FOR OTHER DISEASES MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
13. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
14. UK METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
15. GERMANY METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
16. FRANCE METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
17. SPAIN METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
18. ITALY METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
19. REST OF EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
